Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Tyra Biosciences, Inc. TYRA

Healthcare  —  Biotechnology
21.76 (0.65) (2.90%) as of 25 Sep
Market cap
$1.5B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Tyra Biosciences, Inc. (TYRA) Business Profile

Updated before January 2025

Company Overview

Tyra Biosciences, Inc. (TYRA) is a biotechnology company dedicated to developing innovative therapies for patients with unmet medical needs. Founded in 2018 and headquartered in Carlsbad, California, TYRA focuses on precision medicine, leveraging its proprietary SNÅP platform to design and develop novel small molecule therapies. The company was established by a team of seasoned professionals with extensive experience in drug discovery and development. Key leadership includes Todd Harris, the CEO, who brings a wealth of expertise in biotechnology and life sciences, and other executives with strong backgrounds in research, clinical development, and commercialization.

TYRA’s mission is to transform the treatment landscape for patients by addressing critical gaps in current therapies. The company is committed to advancing science and innovation to deliver life-changing solutions for patients worldwide.

Core Business Segments

Oncology

TYRA’s primary focus is on oncology, where it develops targeted therapies for cancer patients. The company is particularly interested in addressing resistance mechanisms in cancer treatment. TYRA’s lead product candidates are designed to inhibit specific genetic mutations that drive cancer progression, offering a more personalized approach to treatment.

Rare Diseases

In addition to oncology, TYRA is exploring therapies for rare genetic diseases. These conditions often lack effective treatments, and TYRA aims to fill this gap by leveraging its SNÅP platform to develop targeted solutions.

SNÅP Platform

The SNÅP platform is TYRA’s proprietary drug discovery engine. It enables the rapid design and optimization of small molecule therapies by integrating computational modeling, structural biology, and medicinal chemistry. This platform is a cornerstone of TYRA’s business, driving innovation across its product pipeline.

Business Model

TYRA operates on a research-driven business model, focusing on the discovery and development of novel therapies. The company generates revenue through partnerships, licensing agreements, and potential future product sales. By leveraging its SNÅP platform, TYRA aims to accelerate drug development timelines and reduce costs, creating value for both patients and stakeholders.

TYRA’s approach involves:

  • In-House Research and Development: Conducting extensive preclinical and clinical research to validate its drug candidates.
  • Collaborations: Partnering with academic institutions, research organizations, and pharmaceutical companies to enhance its capabilities and expand its reach.
  • Intellectual Property: Protecting its innovations through robust patent filings, ensuring a competitive edge in the market.

Strategic Direction

TYRA is focused on expanding its pipeline of targeted therapies, with a particular emphasis on oncology and rare diseases. The company plans to:

  • Advance Clinical Trials: Progress its lead candidates through clinical development to achieve regulatory approval.
  • Expand the SNÅP Platform: Enhance the capabilities of its drug discovery engine to address a broader range of diseases.
  • Pursue Strategic Partnerships: Collaborate with industry leaders to accelerate development and commercialization efforts.
  • Commit to Sustainability: Integrate sustainable practices into its operations, including reducing its environmental footprint and promoting ethical research practices.

Competitive Landscape

TYRA operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Blueprint Medicines: Known for its precision therapies targeting genetic drivers of disease.
  • Mirati Therapeutics: Focused on oncology and targeted therapies.
  • Relay Therapeutics: Specializing in small molecule drug discovery using computational approaches.

Despite the competition, TYRA differentiates itself through its SNÅP platform, which enables rapid and efficient drug discovery.

Risk Factors

TYRA faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The drug development process is subject to stringent regulatory requirements, which can delay or prevent product approvals.
  • Market Dependence: TYRA’s success depends on the commercial viability of its therapies, which may face competition or fail to meet market expectations.
  • Supply Chain Disruptions: The company relies on a global supply chain for raw materials and manufacturing, which could be affected by geopolitical events or natural disasters.
  • Financial Risks: As a pre-revenue company, TYRA depends on external funding to support its operations, making it vulnerable to market fluctuations.

Recent Developments

TYRA has made significant progress in advancing its pipeline and expanding its capabilities. Recent highlights include:

  • Clinical Milestones: Initiating Phase 1 clinical trials for its lead oncology candidate, demonstrating promising preclinical results.
  • Platform Enhancements: Upgrading the SNÅP platform to improve drug design efficiency and accuracy.
  • Strategic Partnerships: Collaborating with leading academic institutions to explore new therapeutic areas.
  • Global Developments: Navigating the challenges posed by the COVID-19 pandemic, including supply chain disruptions and shifts in clinical trial timelines.

Investment Considerations

Strengths

  • Innovative Platform: The SNÅP platform provides a competitive edge in drug discovery and development.
  • Focused Pipeline: TYRA’s targeted approach addresses unmet medical needs, offering significant market potential.
  • Experienced Leadership: The management team brings extensive expertise in biotechnology and drug development.

Risks

  • Early-Stage Company: As a pre-revenue company, TYRA faces financial and operational risks.
  • Regulatory Hurdles: The drug approval process is lengthy and uncertain.
  • Competitive Market: TYRA operates in a crowded space with established players.

Conclusion

Tyra Biosciences, Inc. is a promising biotechnology company with a strong focus on precision medicine. Its innovative SNÅP platform and targeted approach to drug development position it as a potential leader in the industry. While the company faces challenges typical of early-stage biotech firms, its commitment to innovation and patient-centric solutions offers significant growth opportunities. Investors should weigh the potential rewards against the inherent risks, keeping an eye on TYRA’s progress in clinical development and strategic initiatives.